Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax®-Enabled Pandemic Influenza Vaccine

OXFORD, England, May 4, 2021 /PRNewswire/ — Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent thr… Read full article

Leave a comment

Your email address will not be published. Required fields are marked *